Drugs / Rheosorbilact®
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03771170 | Jan 2018 → Dec 2019 | peritonitis, poisoning | Yuria-Pharm | Completed | No outcome recorded |
| Phase 4 | NCT03824457 | Jan 2018 → Feb 2020 | pneumonia | Yuria-Pharm | Completed | No outcome recorded |
| Phase 4 | NCT04152096 | Feb 2017 → Sep 2020 | poisoning | Yuria-Pharm | Completed | No outcome recorded |
| Phase 4 | NCT03764085 | Dec 2016 → Dec 2019 | infectious disease with sepsis | Yuria-Pharm | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rheosorbilact | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03771170 ↗ |
| Route | Intravenous | “Administered intravenously” NCT03764085 ↗ |